CN1403138A - 一种治疗泌尿系统感染和前列腺炎的中药复方制剂及制备 - Google Patents
一种治疗泌尿系统感染和前列腺炎的中药复方制剂及制备 Download PDFInfo
- Publication number
- CN1403138A CN1403138A CN 02137224 CN02137224A CN1403138A CN 1403138 A CN1403138 A CN 1403138A CN 02137224 CN02137224 CN 02137224 CN 02137224 A CN02137224 A CN 02137224A CN 1403138 A CN1403138 A CN 1403138A
- Authority
- CN
- China
- Prior art keywords
- preparation
- herba
- extractum
- treatment
- compound chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 230000002485 urinary effect Effects 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 title claims abstract description 17
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 17
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 17
- 241000242759 Actiniaria Species 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000012567 medical material Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 229940074391 gallic acid Drugs 0.000 claims description 7
- 235000004515 gallic acid Nutrition 0.000 claims description 7
- 238000007796 conventional method Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 206010018612 Gonorrhoea Diseases 0.000 claims description 5
- 208000001786 gonorrhea Diseases 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 28
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 208000004880 Polyuria Diseases 0.000 abstract description 13
- 230000035619 diuresis Effects 0.000 abstract description 13
- 208000002193 Pain Diseases 0.000 abstract description 12
- 230000036407 pain Effects 0.000 abstract description 12
- 238000001816 cooling Methods 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 235000005206 Hibiscus Nutrition 0.000 abstract description 2
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 abstract description 2
- 244000284380 Hibiscus rosa sinensis Species 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 235000016993 Agrimonia Nutrition 0.000 abstract 1
- 244000307697 Agrimonia eupatoria Species 0.000 abstract 1
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 240000007171 Imperata cylindrica Species 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 36
- 210000002700 urine Anatomy 0.000 description 36
- 230000027939 micturition Effects 0.000 description 26
- 210000004908 prostatic fluid Anatomy 0.000 description 19
- 230000001154 acute effect Effects 0.000 description 18
- 208000019206 urinary tract infection Diseases 0.000 description 17
- 210000001015 abdomen Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000003440 toxic substance Substances 0.000 description 9
- 238000002562 urinalysis Methods 0.000 description 9
- 231100000614 poison Toxicity 0.000 description 8
- 206010048245 Yellow skin Diseases 0.000 description 7
- 230000023597 hemostasis Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 238000000386 microscopy Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 208000008035 Back Pain Diseases 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 208000008930 Low Back Pain Diseases 0.000 description 5
- 208000013507 chronic prostatitis Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000001047 pyretic effect Effects 0.000 description 5
- 210000002105 tongue Anatomy 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 4
- AKGWXHYTRBFUAD-SXOMAYOGSA-N Daphnoline Chemical compound C([C@@H]1N(C)CCC=2C=C(C(=C(OC3=C(OC)C=C4CCN[C@@H](C4=C3)CC=3C=C(C(=CC=3)O)O3)C=21)O)OC)C1=CC=C3C=C1 AKGWXHYTRBFUAD-SXOMAYOGSA-N 0.000 description 4
- 241000588769 Proteus <enterobacteria> Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 235000021251 pulses Nutrition 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 210000003708 urethra Anatomy 0.000 description 4
- 210000002229 urogenital system Anatomy 0.000 description 4
- NWUMSRKLBRWRAS-UHFFFAOYSA-N Arundoin Natural products COC1CCC2(C)C(CCC3C2=CCC4(C)C5CC(C)(C)CCC5(C)CCC34C)C1(C)C NWUMSRKLBRWRAS-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- SVMNNRZZJAFEJM-NSOVKSMOSA-N isotrilobine Chemical compound C([C@@H]1N(C)CC2)C(C=C3)=CC=C3OC(=C3)C(OC)=CC=C3C[C@@H](C3=C4)N(C)CCC3=CC3=C4OC4=C1C2=CC(OC)=C4O3 SVMNNRZZJAFEJM-NSOVKSMOSA-N 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- MRNPHCMRIQYRFU-UWAWSDATSA-N Cylindrin Chemical compound C([C@@]1(C)[C@H](C(C)C)CC[C@@H]1[C@@]1(C)CC=C23)C[C@@]1(C)[C@@H]3CC[C@@H]1[C@]2(C)CC[C@H](OC)C1(C)C MRNPHCMRIQYRFU-UWAWSDATSA-N 0.000 description 2
- BRQBMPGDACUHNR-UHFFFAOYSA-N Cylindrin Natural products COC1CCC2(C)C(CCC3C2=CCC4(C)C5CCC(C(C)C)C5CCC34C)C1(C)C BRQBMPGDACUHNR-UHFFFAOYSA-N 0.000 description 2
- ZKHQJCUUEXSGCM-GDLZYMKVSA-N Epistephanine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OC)C(OC)=CC3=C2C1=NCC3 ZKHQJCUUEXSGCM-GDLZYMKVSA-N 0.000 description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- AKGWXHYTRBFUAD-UHFFFAOYSA-N Trilobamine Natural products O1C(C(=CC=2)O)=CC=2CC(C2=C3)NCCC2=CC(OC)=C3OC(C=23)=C(O)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 AKGWXHYTRBFUAD-UHFFFAOYSA-N 0.000 description 2
- XZAXGQMTBGFTFE-SVBPBHIXSA-N Trilobine Chemical compound C([C@@H]1NCC2)C(C=C3)=CC=C3OC(=C3)C(OC)=CC=C3C[C@@H](C3=C4)N(C)CCC3=CC3=C4OC4=C1C2=CC(OC)=C4O3 XZAXGQMTBGFTFE-SVBPBHIXSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 108010089310 cylindrin Proteins 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 238000009527 percussion Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- MRNPHCMRIQYRFU-KXUMSINMSA-N Arundoin Chemical compound C([C@]1(C)[C@@H](C(C)C)CC[C@H]1[C@]1(C)CC=C23)C[C@]1(C)[C@H]3CC[C@@H]1[C@]2(C)CC[C@H](OC)C1(C)C MRNPHCMRIQYRFU-KXUMSINMSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- XZAXGQMTBGFTFE-UHFFFAOYSA-N D-Trilobin Natural products C1CNC2CC(C=C3)=CC=C3OC(=C3)C(OC)=CC=C3CC(C3=C4)N(C)CCC3=CC3=C4OC4=C2C1=CC(OC)=C4O3 XZAXGQMTBGFTFE-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010015287 Erythropenia Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000048199 Hibiscus mutabilis Species 0.000 description 1
- 235000003973 Hibiscus mutabilis Nutrition 0.000 description 1
- SVMNNRZZJAFEJM-UHFFFAOYSA-N Isotrilobine Natural products C1CN(C)C2CC(C=C3)=CC=C3OC(=C3)C(OC)=CC=C3CC(C3=C4)N(C)CCC3=CC3=C4OC4=C2C1=CC(OC)=C4O3 SVMNNRZZJAFEJM-UHFFFAOYSA-N 0.000 description 1
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000021891 Micturition disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- -1 drying Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000027692 gas pain Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 231100001084 no genetic toxicology Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
尿液 | 治疗后 | 71 17 5 2 0 95 | ||
红细胞 | 治疗前 | 57 19 11 5 3 95 | P<0.05 | |
治疗后 | 80 14 1 0 0 95 | |||
尿蛋白 | 治疗前 | 78 11 4 2 0 95 | P>0.05 | |
治疗后 | 90 2 2 1 0 95 | |||
尿培养 | 治疗前 | 0 24 24 | P<0.01 | |
治疗后 | 22 2 24 | |||
前列腺液 | 白细胞 | 治疗前 | 0 1 5 2 2 10 | |
治疗后 | 8 2 0 0 0 10 | |||
培养 | 治疗前 | 0 5 5 | ||
治疗后 | 2 3 5 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02137224 CN1212134C (zh) | 2002-09-28 | 2002-09-28 | 一种治疗泌尿系统感染和前列腺炎的中药复方制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02137224 CN1212134C (zh) | 2002-09-28 | 2002-09-28 | 一种治疗泌尿系统感染和前列腺炎的中药复方制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1403138A true CN1403138A (zh) | 2003-03-19 |
CN1212134C CN1212134C (zh) | 2005-07-27 |
Family
ID=4748921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02137224 Expired - Lifetime CN1212134C (zh) | 2002-09-28 | 2002-09-28 | 一种治疗泌尿系统感染和前列腺炎的中药复方制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1212134C (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104667004A (zh) * | 2015-03-12 | 2015-06-03 | 贵阳新天药业股份有限公司 | 宁泌泰在治疗妇科炎症药物中的用途 |
CN104825906A (zh) * | 2015-06-03 | 2015-08-12 | 贵阳新天药业股份有限公司 | 一种治疗前列腺的中药组合物和中药制剂及其应用 |
CN104825907A (zh) * | 2015-06-03 | 2015-08-12 | 贵阳新天药业股份有限公司 | 一种治疗泌尿系统感染的中药组合物和中药制剂及其应用 |
CN104825908A (zh) * | 2015-06-03 | 2015-08-12 | 贵阳新天药业股份有限公司 | 一种治疗不育症的中药组合物和中药制剂及其应用 |
CN104857352A (zh) * | 2015-06-03 | 2015-08-26 | 贵阳新天药业股份有限公司 | 一种治疗妊娠期妇科疾病的中药组合物和中药制剂及其应用 |
CN104857353A (zh) * | 2015-06-03 | 2015-08-26 | 贵阳新天药业股份有限公司 | 一种治疗妇科疾病的中药组合物和中药制剂及其应用 |
CN105288307A (zh) * | 2015-12-01 | 2016-02-03 | 臧海阳 | 一种治疗阴虚湿热型泌尿系感染的中药组合物 |
CN105709098A (zh) * | 2016-03-22 | 2016-06-29 | 贵阳新天药业股份有限公司 | 一种泌尿系统感染和前列腺炎制剂的干法制粒方法 |
CN105796957A (zh) * | 2016-03-31 | 2016-07-27 | 贵州省中国科学院天然产物化学重点实验室 | 盐酸坦索罗辛与宁泌泰在制备联合用抗菌药物中的应用及其产品 |
CN111544535A (zh) * | 2020-06-19 | 2020-08-18 | 贵阳新天药业股份有限公司 | 一种用于抑制大肠埃希菌及其生物膜的中药复方制剂及其用途 |
CN111686211A (zh) * | 2020-06-19 | 2020-09-22 | 贵阳新天药业股份有限公司 | 一种用于改善精液质量的中药复方制剂及其用途 |
CN115845002A (zh) * | 2023-01-17 | 2023-03-28 | 贵阳新天药业股份有限公司 | 一种改善ⅲb型前列腺炎患者疼痛症状的药物及其应用 |
CN116270912A (zh) * | 2023-03-23 | 2023-06-23 | 贵阳新天药业股份有限公司 | 一种预防和/或治疗前列腺疾病的药物组合物及制备方法和应用 |
-
2002
- 2002-09-28 CN CN 02137224 patent/CN1212134C/zh not_active Expired - Lifetime
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104667004A (zh) * | 2015-03-12 | 2015-06-03 | 贵阳新天药业股份有限公司 | 宁泌泰在治疗妇科炎症药物中的用途 |
CN104825906A (zh) * | 2015-06-03 | 2015-08-12 | 贵阳新天药业股份有限公司 | 一种治疗前列腺的中药组合物和中药制剂及其应用 |
CN104825907A (zh) * | 2015-06-03 | 2015-08-12 | 贵阳新天药业股份有限公司 | 一种治疗泌尿系统感染的中药组合物和中药制剂及其应用 |
CN104825908A (zh) * | 2015-06-03 | 2015-08-12 | 贵阳新天药业股份有限公司 | 一种治疗不育症的中药组合物和中药制剂及其应用 |
CN104857352A (zh) * | 2015-06-03 | 2015-08-26 | 贵阳新天药业股份有限公司 | 一种治疗妊娠期妇科疾病的中药组合物和中药制剂及其应用 |
CN104857353A (zh) * | 2015-06-03 | 2015-08-26 | 贵阳新天药业股份有限公司 | 一种治疗妇科疾病的中药组合物和中药制剂及其应用 |
CN105288307A (zh) * | 2015-12-01 | 2016-02-03 | 臧海阳 | 一种治疗阴虚湿热型泌尿系感染的中药组合物 |
CN105709098A (zh) * | 2016-03-22 | 2016-06-29 | 贵阳新天药业股份有限公司 | 一种泌尿系统感染和前列腺炎制剂的干法制粒方法 |
CN105796957A (zh) * | 2016-03-31 | 2016-07-27 | 贵州省中国科学院天然产物化学重点实验室 | 盐酸坦索罗辛与宁泌泰在制备联合用抗菌药物中的应用及其产品 |
CN111544535A (zh) * | 2020-06-19 | 2020-08-18 | 贵阳新天药业股份有限公司 | 一种用于抑制大肠埃希菌及其生物膜的中药复方制剂及其用途 |
CN111686211A (zh) * | 2020-06-19 | 2020-09-22 | 贵阳新天药业股份有限公司 | 一种用于改善精液质量的中药复方制剂及其用途 |
CN115845002A (zh) * | 2023-01-17 | 2023-03-28 | 贵阳新天药业股份有限公司 | 一种改善ⅲb型前列腺炎患者疼痛症状的药物及其应用 |
CN116270912A (zh) * | 2023-03-23 | 2023-06-23 | 贵阳新天药业股份有限公司 | 一种预防和/或治疗前列腺疾病的药物组合物及制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1212134C (zh) | 2005-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1768812A (zh) | 一种用于除湿止痒的药物组合物及其制备方法和用途 | |
CN1212134C (zh) | 一种治疗泌尿系统感染和前列腺炎的中药复方制剂 | |
CN111544550B (zh) | 中药配方菌群胶囊及制备方法和在制备治疗2型糖尿病的药物中的应用 | |
CN112353855A (zh) | 中药组合物在制备辅助治疗新型冠状病毒肺炎的药物中的应用 | |
CN1772081A (zh) | 一种治疗腹泻病的中药组合物 | |
CN101041009A (zh) | 一种治疗咽喉炎的中药药物 | |
CN1210047C (zh) | 治疗感冒的药物及其制备方法 | |
CN1304735A (zh) | 一种治疗慢性结肠炎的药物 | |
CN1197612C (zh) | 治疗泌尿系统结石和尿路感染疾病的中药制剂及其制备方法 | |
CN1698691A (zh) | 一种治疗肺热(毒)咳嗽的药物及其制备方法 | |
JP7157253B2 (ja) | 潤腸便通の漢方薬組成物、その調製方法及びその用途 | |
CN1240412C (zh) | 一种治疗痔疮的中药复方制剂及其制备方法 | |
CN102274428B (zh) | 一种具有治疗肠易激综合症作用的药物组合物及其制备方法和应用 | |
CN1679692A (zh) | 一种治疗淋病的药物及其制备方法 | |
CN1148217C (zh) | 治疗慢性支气管炎的中成药 | |
CN1237983C (zh) | 复方贯众阿司匹林制剂 | |
CN1298351C (zh) | 一种治疗泌尿系感染的中药口服制剂及其制备方法 | |
CN104491637B (zh) | 一种治疗感冒后咳嗽的复方组合药物及其制备方法与应用 | |
CN1682974A (zh) | 一种治疗急性咽喉炎症的中药制剂及其制备方法 | |
CN1284594C (zh) | 一种治疗良性前列腺增生症的复方中药制剂及制备工艺 | |
CN1261156C (zh) | 一种治疗慢性胃肠炎、结肠炎的药物 | |
CN1718225A (zh) | 治疗肝功能损害的复方中药制剂及其制备 | |
CN1061256C (zh) | 外涂降压膏 | |
CN1193777C (zh) | 感冒脐疗中药制剂及其生产方法 | |
CN1634340A (zh) | 一种防治少儿呼吸系统疾病的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20090617 Pledge (preservation): Pledge |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20120412 Granted publication date: 20050727 Pledgee: Agricultural Bank of China Guiyang Wudang District subbranch Pledgor: GUIYANG XIN TIAN PHARMACEUTICAL Co.,Ltd. Registration number: 2009520000562 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound Chinese medicine prepn for treating urinary system infection and prostatitis and its prepn process Effective date of registration: 20120412 Granted publication date: 20050727 Pledgee: Agricultural Bank of China Limited by Share Ltd. Guiyang Wudang branch Pledgor: GUIYANG XIN TIAN PHARMACEUTICAL Co.,Ltd. Registration number: 2012990000144 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150423 Granted publication date: 20050727 Pledgee: Agricultural Bank of China Limited by Share Ltd. Guiyang Wudang branch Pledgor: GUIYANG XIN TIAN PHARMACEUTICAL Co.,Ltd. Registration number: 2012990000144 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound Chinese medicine prepn for treating urinary system infection and prostatitis and its prepn process Effective date of registration: 20150630 Granted publication date: 20050727 Pledgee: Industrial Commercial Bank of China Ltd. Guiyang Wudang branch Pledgor: GUIYANG XIN TIAN PHARMACEUTICAL Co.,Ltd. Registration number: 2015520000003 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201023 Granted publication date: 20050727 Pledgee: Industrial Commercial Bank of China Ltd. Guiyang Wudang branch Pledgor: GUIYANG XIN TIAN PHARMACEUTICAL Co.,Ltd. Registration number: 2015520000003 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20050727 |